Surmodics Reports Second Quarter Fiscal 2021 Results and Issues Fiscal 2021 Revenue and EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
SurModics (SRDX) PT Raised to $68 at Needham & Company Following Earnings
April 28, 2021 3:59 PM EDTNeedham & Company analyst Mike Matson raised the price target on SurModics (NASDAQ: SRDX) to $68.00 (from $61.00) while maintaining a Buy rating.
The analyst commented, "SRDX F2Q21 revenue and EPS beat consensus. Revenue growth improved to 53.3% in F2Q21 from (1.4%) in... More
SurModics (SRDX) Misses Q2 EPS by 1c, Revenues Beat; Offers FY21 EPS Guidance Below Consensus, FY21 Revs. Mid-Point View Above Consensus
April 28, 2021 7:40 AM EDTSurModics (NASDAQ: SRDX) reported Q2 EPS of $0.62, $0.01 worse than the analyst estimate of $0.63. Revenue for the quarter came in at $35 million versus the consensus estimate of $32.95 million.
Summary of Second Quarter and Recent Highlights
Revenue of $35.0 million, an increase of 53% year-over-yearGAAP EPS of $0.58, non-GAAP EPS of $0.62Successful first patient uses of two Sublime radial access... More